Persistence of Varicella Zoster Virus DNA in Saliva After Herpes Zoster

Departments of Neurology, University of Colorado School of Medicine, Aurora, CO, USA.
The Journal of Infectious Diseases (Impact Factor: 6). 09/2011; 204(6):820-4. DOI: 10.1093/infdis/jir425
Source: PubMed


Analysis of saliva samples from individuals aged ≥ 60 years who had a history of zoster (group 1), zoster and postherpetic neuralgia (PHN; group 2), or no history of zoster (group 3) revealed varicella zoster virus (VZV) DNA in saliva samples from 11 of 17 individuals in group 1, 10 of 15 individuals in group 2, and 2 of 17 individuals in group 3. The frequency of VZV DNA detection was significantly higher (P = .001) in saliva of subjects with a history of zoster, with or without PHN (21 [67%] of 32 subjects in groups 1 and 2), than in saliva of age-matched subjects with no zoster history (2 [12%] of 17 subjects in group 3). Thus, persistence of VZV DNA in saliva is the outcome of zoster, independent of PHN. Because VZV infection can produce neurological and ocular disease without zoster rash, future studies are needed to establish whether VZV DNA can be detected in the saliva of such patients.

Download full-text


Available from: Randall J Cohrs,
  • Source
    • "on , VZV is assumed to remain latent , but capable of reactivation . The frequencies of VZV reactivation used in the parameter sets were informed by observed VZV reactivation frequencies in random samples from healthy individuals ( 2% in blood [ Schünemann et al . , 1997 ] ; 0 out of 112 saliva samples [ Mehta et al . , 2003 ] ; 2 . 5% in saliva [ Nagel et al . , 2011 ] ) , immunosuppressed patients ( 8 . 1% from various sites [ Engelmann et al . , 2008 ] ) , individuals with malignancies ( 7 . 5% in blood [ Malavige et al . , 2010 ] ) and HIV patients ( 9% in saliva [ van Velzen et al . , 2013 ] ; 16% in cerebrospinal fluid [ Birlea et al . , 2011 ] ) . The consequence of reactivation can either be "
    [Show abstract] [Hide abstract]
    ABSTRACT: Varicella-zoster virus (VZV) causes chickenpox and reactivation of latent VZV causes herpes zoster (HZ). VZV reactivation is subject to the opposing mechanisms of declining and boosted VZV-specific cellular mediated immunity (CMI). A reduction in exogenous re-exposure 'opportunities' through universal chickenpox vaccination could therefore lead to an increase in HZ incidence. We present the first individual-based model that integrates within-host data on VZV-CMI and between-host transmission data to simulate HZ incidence. This model allows estimating currently unknown pivotal biomedical parameters, including the duration of exogenous boosting at 2 years, with a peak threefold to fourfold increase of VZV-CMI; the VZV weekly reactivation probability at 5% and VZV subclinical reactivation having no effect on VZV-CMI. A 100% effective chickenpox vaccine given to 1 year olds would cause a 1.75 times peak increase in HZ 31 years after implementation. This increase is predicted to occur mainly in younger age groups than is currently assumed.
    eLife Sciences 08/2015; 4. DOI:10.7554/eLife.07116 · 9.32 Impact Factor
  • Source
    • "Furthermore, recent studies have clearly indicated that most patients with HZ have viremia which may persist for months, while VZV DNA viral load is associated with longer duration of symptoms and risk factors for PHN [Quinlivan et al. 2007, 2011]. Moreover, VZV DNA has been detected in the saliva of 100%, 52% and 59% of patients with acute HZ, Ramsey Hunt syndrome and zoster sine herpete, respectively [Furuta et al. 2001; Nagel et al. 2011]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Varicella is a highly contagious disease caused by primary infection with varicella zoster virus (VZV). VZV infection, as well as varicella vaccination, induces VZV-specific antibody and T-cell-mediated immunity, essential for recovery. The immune responses developed contribute to protection following re-exposure to VZV. When cell-mediated immunity declines, as occurs with aging or immunosuppression, reactivation of VZV leads to herpes zoster (HZ). It has been almost 20 years since universal varicella vaccination has been implemented in many areas around the globe and this has resulted in a significant reduction of varicella-associated disease burden. Successes are reviewed here, whilst emphasis is put on the challenges ahead. Most countries that have not implemented routine childhood varicella vaccination have chosen to vaccinate high-risk groups alone. The main reasons for not introducing universal vaccination are discussed, including fear of age shift of peak incidence age and of HZ incidence increase. Possible reasons for not observing the predicted increase in HZ incidence are explored. The advantages and disadvantages of universal vs targeted vaccination as well as different vaccination schedules are discussed.
    03/2014; 2(2):39-55. DOI:10.1177/2051013613515621
  • Source

    The Journal of Infectious Diseases 03/2012; 205(9):1331-3. DOI:10.1093/infdis/jis214 · 6.00 Impact Factor
Show more